ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
43 announcements with these filters
Ind-Swift Laboratories entered a ₹40 Crore MOU with Him Infratech to build a warehouse facility in Punjab. The project aims to improve storage and operational efficiencies.
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as of June 30, 2026, in compliance with SEBI regulatory requirements.
Ind-Swift Laboratories convened an EGM for August 5, 2026. Key agendas include issuing 70 lakh convertible warrants to promoters and re-appointing an Independent Director.
Ind-Swift Laboratories convened an EGM for August 05, 2026. Agenda includes a Rs. 137.20 Crore preferential warrant issuance to promoter entity Essix Biosciences.
Ind-Swift Laboratories approved a Rs. 137.20 Crore preferential issue of 70 lakh warrants to Essix Biosciences Limited. Warrants are convertible within 18 months.
Ind-Swift Labs will hold a Board Meeting on July 10, 2026, to consider fund raising. Trading window is closed until 48 hours after the meeting.
Ind-Swift Laboratories has re-appointed M/s. V Kumar & Associates as Cost Auditors for a 12-month term. This routine regulatory compliance ensures continued oversight of the company's cost records.
Ind-Swift Laboratories allotted 1,25,000 equity shares under its ESOP 2014 scheme. The company's paid-up share capital increased to 86,96,15,580 shares following this allotment.
Ind-Swift Laboratories allotted 1,25,000 equity shares under its 2014 ESOP scheme. This increases paid-up capital to ₹86.96 Crore, rewarding employees and expanding the share base.
Ind-Swift Laboratories reported zero deviation in the utilization of ₹255.61 Crore raised via preferential warrants. The funds were deployed towards business expansion, investments, and working capital.
Ind-Swift Laboratories Ltd reported revenue from operations of ₹169.8 Cr (+19.2% YoY) and net profit of ₹15.1 Cr (-93.2% YoY) for Q4 FY26.
Ind-Swift Laboratories approved its FY26 audited financial results and re-appointed V. Kumar & Associates as cost auditors. Performance reflects full-year operations post-amalgamation with Ind Swift Limited.
Ind-Swift Laboratories scheduled a board meeting for May 28, 2026, to approve audited financial results. Investors should track the subsequent outcome for performance data.